Information Provided By: 
Fly News Breaks for May 15, 2017
IONS, BIIB
May 15, 2017 | 10:09 EDT
Piper Jaffray analyst Joshua Schimmer raised his price target for Biogen (BIIB) to $442 citing higher confidence in aducanumab following this morning's data from Ionis Pharmaceuticals (IONS). The data from Ionis validate that mobilization of amyloid from peripheral nerves in a disease caused by amyloidosis can have meaningful clinical benefit, Schimmer tells investors in a research note. He keeps an Overweight rating on Biogen.
News For BIIB;IONS From the Last 2 Days
